Core Viewpoint - Dyadic International, Inc. has announced a public offering of 6,052,000 shares of common stock at a price of $0.95 per share, expecting gross proceeds of approximately $5.75 million before expenses [1][2]. Group 1: Offering Details - The public offering is managed by Craig-Hallum Capital Group LLC, and the closing is anticipated on August 1, 2025, subject to customary conditions [1][2]. - The net proceeds from the offering will be utilized for working capital and general corporate purposes, including product development and sales and marketing [2]. Group 2: Company Background - Dyadic International is a global biotechnology company that focuses on scalable production of precision-engineered functional input proteins for various applications in life sciences, food and nutrition, and industrial biotechnology [1][5]. - The company utilizes proprietary gene expression platforms, specifically its C1 and Dapibus™ systems, to produce high-quality recombinant proteins for partners in multiple markets [5].